Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04670965 · ClinicalTrials.gov registry record
Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis
A clinical trial, sponsored by University of Alabama at Birmingham.
- Not yet
- Registry status
- 20
- Enrollment target
NCT04670965 is a clinical trial that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants.
The verdict
NCT04670965 has not yet begun recruiting, sponsored by University of Alabama at Birmingham.
- NOT YET RECRUITING
- Registry status
- 20 participants
- Enrollment target
Study Summary
This study is seeking to evaluate the binding of a commercially-available, recombinant human osteoinductive growth factor, rhBMP-2, to a human blood derived product scaffold, enhanced Platelet-rich fibrin (E-PRF), and the release of such a growth factor over time in an in vitro (laboratory) environment. The investigators will compare these release kinetics to those of the FDA approved carrier for rhBMP-2, an absorbable collagen sponge (ACS), a combination of E-PRF and ACS, and E-PRF alone.
Interventions
- BIOLOGICAL E-PRF/rhBMP-2 (similar ratios)
- BIOLOGICAL E-PRF/ACS/rhBMP-2
- BIOLOGICAL rhBMP-2/E-PRF
- BIOLOGICAL E-PRF only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-09 |
| Est. Completion | 2028-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04670965
The ClinicalTrials.gov registry entry for NCT04670965 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which E-PRF/rhBMP-2 (similar ratios) is the first listed.
NCT04670965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04670965 about?
NCT04670965 is a clinical study titled "Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis". This study is seeking to evaluate the binding of a commercially-available, recombinant human osteoinductive growth factor, rhBMP-2, to a human blood derived product scaffold, enhanced Platelet-rich fibrin (E-PRF), and the release of such a growth factor over time in an in vitro (laboratory) environm...
What is the current status of trial NCT04670965?
This trial is currently not yet recruiting. The enrollment target is 20 participants. The study started on 2026-09. Estimated completion is 2028-07.
What interventions are being tested in trial NCT04670965?
The interventions under investigation include: E-PRF/rhBMP-2 (similar ratios) (BIOLOGICAL), E-PRF/ACS/rhBMP-2 (BIOLOGICAL), rhBMP-2/E-PRF (BIOLOGICAL), E-PRF only (BIOLOGICAL).
Who is sponsoring clinical trial NCT04670965?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.